ALLOGENE THERAPEUTICS

Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress

11 май 2023 11:50:32 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

03 май 2023 16:02:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

26 апр 2023 10:06:38 Источник Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023

25 апр 2023 08:30:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

20 апр 2023 16:05:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting

17 апр 2023 10:15:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences

13 апр 2023 08:30:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report

30 мар 2023 08:30:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting

14 мар 2023 17:30:48 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

02 мар 2023 08:30:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy 

01 мар 2023 08:30:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

28 фев 2023 16:02:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023

21 фев 2023 08:30:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology

01 фев 2023 14:55:08 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

25 янв 2023 08:30:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma

24 янв 2023 08:30:16 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

17 янв 2023 16:05:24 Источник Nasdaq GlobeNewswire

Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 янв 2023 08:30:00 Источник Nasdaq GlobeNewswire

Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development

03 янв 2023 08:00:02 Источник Nasdaq GlobeNewswire

Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform

29 ноя 2022 15:30:12 Источник Nasdaq GlobeNewswire